Alzheimer-disease-journals| OMICS International |Brain-Disorders-Therapy

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Alzheimer’s Disease

In Japan, no medicine is permitted for behavioral and psychological symptoms of dementia (BPSD) in Alzheimer’s disease (AD). On the contrary, atypical antipsychotics are inhibited because mortality rate increases when these medicines are prescribed for elderly demented patients. However, antipsychotics are prescribed for BPSD such as delusions, hallucinations, agitations or aggressions with permission of proxies of AD patients. Cognitive function was evaluated using the Mini-Mental State Examination (MMSE) and BPSD were assessed by the Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD). First, according to the age at the time of test, whole AD patients (n=79, WAD) group were divided into two groups, a relative older group in the WAD (with age the time of test were 81 and over, n=40, OG) and a relative younger group in WAD. There are several limitations in the present study these two reports were without control subjects, not observing longitudinal course of cognitive dysfunctions but only cross-sectional. Moreover, these two studies didn’t include “bipolarity” as predictive values. Generally speaking, depressive syndrome (anxieties,phobias, and affective disturbances) are thought to be diminished according to aging and the progression of dementia.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on January, 2021